Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.99 USD
Change Today -0.02 / -1.98%
Volume 61.1K
ATOS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

atossa genetics inc (ATOS) Snapshot

Open
$1.00
Previous Close
$1.01
Day High
$1.01
Day Low
$0.96
52 Week High
02/26/15 - $2.65
52 Week Low
10/15/14 - $0.80
Market Cap
28.8M
Average Volume 10 Days
148.1K
EPS TTM
$-0.55
Shares Outstanding
29.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATOSSA GENETICS INC (ATOS)

Related News

No related news articles were found.

atossa genetics inc (ATOS) Related Businessweek News

No Related Businessweek News Found

atossa genetics inc (ATOS) Details

Atossa Genetics Inc. operates as a healthcare company that focuses on the development of a suite of laboratory services, medical devices, and therapeutics for breast cancer in the United States. The company markets nipple aspirate fluid (NAF) cytology tests and pharmacogenomics tests. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator devices that are intended for the collection of NAF for cytological testing at a laboratory. The company is also involved in the development of other devices comprising intraductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, as well as various tools for potential use by breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

27 Employees
Last Reported Date: 03/30/15
Founded in 2009

atossa genetics inc (ATOS) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $500.0K
Chief Financial Officer, General Counsel and ...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

atossa genetics inc (ATOS) Key Developments

John E. Sawyer Resigns as Senior Vice President, Global Regulatory Affairs and Quality Assurance, of Atossa Genetics Inc, Effective June 8, 2015

On June 3, 2015, John E. Sawyer announced that he is resigning as the Senior Vice President, Global Regulatory Affairs and Quality Assurance, of Atossa Genetics Inc. with an expected effective date of June 8, 2015. Mr. Sawyer is pursuing other professional activities.

Atossa Genetics Inc. Hires Gerald Engley as Senior Director of Medical Affairs

Atossa Genetics Inc. announced that Dr. Gerald Engley has joined the company as Senior Director of Medical Affairs, effective May 26, 2015. Prior to joining the company, Dr. Engley was Senior Director, Global Health Science at The Medicines Company, focusing on development and execution of health science strategies, medical education review, promotional review, and development of formulary dossiers.

Atossa Genetics, Inc. - Special Call

To discuss on corporate developments

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATOS:US $0.99 USD -0.02

ATOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocept Inc $2.34 USD -0.0184
Illumina Inc $218.87 USD +1.68
View Industry Companies
 

Industry Analysis

ATOS

Industry Average

Valuation ATOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.6x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATOSSA GENETICS INC, please visit www.atossagenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.